Recent Updates
Recently added Catalysts

NeoFuse

Phase 2

Cervical Degenerative Disc Disease | Monoclonal antibody | Other |Mesoblast Limited|Last Updated: Jun 29, 2020

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDDMCBiomarker
Total Trials2
Total Enrollment36
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01097486Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical DiscectomyPHASE2 COMPLETED 24Jun 1, 2010Jul 1, 2014Aug 16, 20198 United States
NCT01106417Safety and Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy and FusionPHASE1 COMPLETED 12Jun 1, 2010Mar 1, 2013Jun 29, 20202 Australia
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
To determine the safety of NeoFuse using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and and immunology).
2 years
Safety of NeoFuse
2 years

To determine the safety of NeoFuse using physical examinations, vital signs, treatment emergent adverse events (TEAEs), and the results of clinical lab tests (hematology, serum chemistry, inflammation, and and immunology).

Secondary Endpoints
To evaluate the fusion success with NeoFuse compared to allograft spacer using CT scans and x-ray of the involved cervical spine levels and assess the change in outcomes (NDI, SF-36, Zung Depression Questionnaire, and WPAI.
1 years
Fusion success with NeoFuse
1 year
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
AllograftACTIVE_COMPARATORCervical Spinal Fusion with Allograft
NeoFuseEXPERIMENTALCervical Spinal Fusion with NeoFuse
MasterGraft GranulesACTIVE_COMPARATORAnterior Cervical Discectomy and Fusion with MasterGraft Granules MASTERGRAFT® GRANULES are a medical-grade, polyporous resorbable ceramic hybrid composed of 15% hydroxyapatite (HA) and 85% beta-tricalcium phosphate (β-TCP). The combination of these natural bone materials provides surgeons with an osteoconductive, porous implant that improves osteointegration by allowing cells to colonize throughout the implant and optimize the bone healing process
Interventions
NameTypeDescription
NeoFuseBIOLOGICALSingle Dose NeoFuse Surgical Implantation
AllograftPROCEDURESingle Dose Allograft Surgical Implantation
MasterGraft GranulesDEVICESingle Dose MaterGraft Granules Surgical Implantation
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 70 Years
SexALL
Healthy VolunteersNo
Study Sites8

Inclusion Criteria: 1. Male or females between 18 and 70 years of age, inclusive. 2. Has the ability to understand the requirements of the study, to provide written informed consent, and to comply with the study protocol. 3. Has the ability to understand and provide written authorization for the us...

Countries:United StatesAustralia
Unlock Eligibility Criteria